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US guidelines on the treatment of blood cholesterol received 
mixed reviews immediately after publication and significant 
controversy initiating vivid discussions, not only in Europe 
but also even more in the US, particularly when compared 
with the European ESC/EAS guidelines [4]. Therefore, it is 
important to point out all similarities and especially all the 
significant differences between these two most important 
recent guidelines, in order to stress why is it so important for 
European countries to implement the European guidelines and 
why are they more appropriate for these countries.
There are many similarities between these two sets of 
guidelines, but as the differences are discussed much more, 
the major similarities will be briefly mentioned now and 
some of the differences will be later analysed in detail. The 
major similarities are that both of these guidelines consider 
that increased low-density lipoprotein-cholesterol (LDL-C) is 
unequivocally a causal factor for ASCVD, and both guidelines 
have systematically evaluated scientific evidence and have 
applied the grading systems, but it should be stressed that the 
European guidelines used the same grading system as all the 
other ESC guidelines [5, 6]. Both of them encourage lifestyle 
modification and the engagement of the patient as a partner 
in ASCVD prevention. Both guidelines clearly identify four 
INTRODUCTION
The first European Society of Cardiology/European Athero-
sclerosis Society (ESC/EAS) guidelines for the management of 
dyslipidaemias were published in 2011 [1]. These ESC/EAS 
guidelines are, when dyslipidaemias are concerned, in full 
accordance with more recently published Joint European 
societies guidelines on cardiovascular disease prevention in 
clinical practice (version 2012) [2]. In 2013 the American 
College of Cardiology (ACC) and the American Heart Associa-
tion (AHA) released three documents reporting on guidelines 
for the prevention of atherosclerotic cardiovascular disease 
(ASCVD) — one document on the assessment of cardiovascu-
lar risk, one on lifestyle management to reduce cardiovascular 
risk, and one on “treatment of blood cholesterol to reduce 
atherosclerotic cardiovascular risk in adults”, which is a cor-
responding document to the European ESC/EAS guidelines 
for the management of dyslipidaemias [3]. 
In this review differences and similarities between the 
European ESC/EAS guidelines for dyslipidaemia manage-
ment and United States (US) ACC/AHA guidelines on the 
treatment of blood cholesterol will be commented on. This 
is important since in some European countries there are still 




patient groups at greatest risk of ASCVD: those with estab-
lished ASCVD, those with diabetes mellitus, those with high 
predicted ASCVD risk based on global risk assessment, and 
those with familial hypercholesterolaemia (FH). However, no 
explicit mentioning of FH and no recommendation for these 
patients appears in US guidelines, although some recommen-
dations obviously have to be applied to them [7].
The major differences are: The US guidelines consider 
only and exclusively the evidence originating from randomised 
controlled trials (RCTs) and concentrate only on LDL-C while 
the European guidelines consider mostly RCT evidence, but 
unlike the rigid US approach, they take into consideration 
also all available evidence and not just RCTs. They consider 
also the importance of all lipids and not just LDL-C and 
provide practical guidance across a broader range of lipid 
disturbances, offering much broader pragmatic clinical advise 
on the utility of other lipid fractions such as triglyceride-rich 
lipoproteins, remnants, and conditions associated with low 
levels of high-density lipoprotein-cholesterol (HDL-C) where 
non-HDL-C or apolipoprotein B are more informative, as well 
as lipoprotein (a), which is also considered to be a risk factor 
for ASCVD [8, 9]. The European guidelines also extend the 
scope of the definition of ASCVD to include findings from im-
aging and not simply a clinical presentation, thereby including 
patients at an earlier stage of disease. The European guidelines 
consider chronic kidney disease as a coronary artery disease 
(CAD) equivalent and therefore include these patients in a very 
high risk group who require lipid management with a target 
LDL-C of < 1.8 mmol/L (~70 mg/dL) or a 50% reduction 
in LDL-C whereas the US guidelines do not discuss chronic 
kidney disease patients at all. Another important difference is 
that the US guidelines focus primarily on the treatment pro-
cess whereas the European guidelines focus primarily on the 
treatment results. European guidelines are focused not only 
on LDL-C as a risk factor but on individual patients, which is 
also different from the US guidelines.
RISK ESTIMATION
Since the treatment of dyslipidaemias should always be con-
sidered within the broader framework of ASCVD prevention, 
the assessment of total ASCVD risk is crucial. In European 
guidelines risk estimation is based upon Systemic Coronary 
Risk Estimation (SCORE) [10] while in the US guidelines it is 
based upon Framingham [11], which was used for developing 
a new risk pooled cohort risk calculator. Although most risk 
estimation systems perform rather similarly when applied to 
populations that are comparable to those from which the risk 
estimation system was derived, it has been clearly shown that 
the differences in populations do play a significant role [12, 13].
The SCORE system used in European guidelines estimates 
the 10-year risk of a first fatal ASCVD event (acute myocardial 
infarction, stroke, etc.). It is based upon a very large, repre-
sentative (over 250,000 individuals) population from differ-
ent European countries. The choice of retaining the system 
that estimates ASCVD mortality rather than total (fatal plus 
non-fatal) events in the European guidelines was deliberate. 
There were several reasons for this. Death is undoubtedly 
a hard and reproducible endpoint while a non-fatal event is 
variable and depends upon definitions, diagnostic criteria, 
and diagnostic tests, all of which may vary over time and 
availability in different countries. It is also clear that a high risk 
of ASCVD death automatically indicates a higher risk of total 
events. The use of ASCVD mortality allows re-calibration to 
allow for time-trends and for secular changes if good quality 
up-to-date mortality and risk factor prevalence data are avail-
able [14]. This is the case in all European countries. Unfortu-
nately, data quality does not permit this for non-fatal events, 
at least in a number of European countries in which the data 
on ASCVD events are incomplete, but even more so for many 
non-European countries, excluding the US. 
Since one of the advantages of the SCORE system is that 
it can be re-calibrated for use in different populations and 
adjusted for secular changes in CVD mortality and risk factor 
prevalence, such calibrated country-specific versions exist for 
a number of European countries, including Poland. Of course, 
risk estimation calculator based upon Framingham, as used 
in the US guidelines, can also be re-calibrated for countries 
other than the US, but the process is incomparably easier for 
ASCVD mortality than for total ASCVD events.
Immediately after publication there was a lot of criticism 
towards the recent US guidelines and also towards the new 
US pooled cohort risk calculator upon which these guidelines 
are based. Many have objected that the primary prevention 
threshold used in these guidelines, if applied, would result in 
many more patients receiving statins and in many cases with 
higher doses than are currently used in the US, and even 
more so in Europe. Particularly controversial is the utilisation 
of the new US risk calculator in primary care to determine 
which individuals will require a statin because they empha-
sise 10-year risk of at least 7.5% of ASCVD to identify adults 
75 years of age or younger and with no established ASCVD 
as eligible for statin therapy for primary prevention [15]. This 
10-year threshold of 7.5% corresponds to a 2.5% risk for 
ASCVD death over 10 years in the SCORE model used in the 
European guidelines and represents a much lower threshold 
for 10-year risk of fatal and non-fatal ASCVD. In SCORE those 
with a 10-year risk of fatal ASCVD of 2.5% are considered at 
moderate risk, and the European guidelines recommendation 
is that an LDL-C of < 3 mmol/L (~ 115 mg/dL) is acceptable in 
them. Thus, while the European guidelines allow some scope 
by virtue of an LDL-C target for lifestyle intervention before 
lipid-lowering drug therapy is introduced, patients are more 
likely to be treated immediately with statins following the 
recent US guidelines. A particular problem seems to be that 
according to the US guidelines practically all subjects older 
than 70 years, because of the impact of age on 10-year ASCVD 
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risk according to the US risk calculator, should be prescribed 
moderate- to high-intensity statin treatment.
Using the National Cardiovascular Data Registry Practice 
Innovation and Clinical Excellence (NCDR PINNACLE) registry 
data from 2008 to 2012 and a cohort of 1,174,545 patients, it 
has been recently established that achieving concordance with 
the recent US guidelines in patients treated in different US 
cardiovascular practices would result in significant increases 
in statin use, as well as significant reductions in non-statin 
therapies and laboratory testing [16]. The most recent analysis 
to date, which included 4,227 patients from the Multi-Ethnic 
Study of Atherosclerosis (MESA) aged 50–74 years, who were 
followed for 10.2 years, showed that the new US risk calcula-
tor used in the recent US guidelines, overestimated the risk 
of ASCVD endpoints by 86% in men and 67% in women. 
Overall, the US risk score overestimated risk by a net 78% [17]. 
The editorial that accompanied this paper stressed that such 
an overestimation is very important as some patients might, 
due to grossly overestimated risk, end up on lifelong statin 
therapy, and that a 7.5% risk of ASCVD events at 10 years 
does not automatically mandate the start of statin therapy 
[18]. This overestimation is particularly evident when some 
specific subpopulations are concerned [19]. Finally, there 
are data indicating that implementation of these recent US 
guidelines would increase the number of adults who would 
be eligible for statin therapy in the US by 12.8 million, with 
the increase seen mostly among older adults without ASCVD 
[20] for whom studies have not consistently demonstrated an 
overall beneficial effect of such a treatment on total mortality 
[21]. So it seems that the serious concern that the risk calcula-
tor used by the recent US guidelines will generally overpredict 
ASCVD risk is absolutely justified.
WHY MIGHT OVERESTIMATION  
OF ASCVD RISK BE SO IMPORTANT?
Possible overestimating of the risk is not only important 
because of drastically increased expenditures to the public 
health budget caused by significantly increased numbers of 
individuals who should therefore be treated lifelong with 
statins, but much more because of a higher incidence of ad-
verse effects of statins when prescribed so extensively. These 
adverse effects include myopathy, which is most often defined 
as an increase in creatinine kinase > 10 times the upper limit 
of normal (ULN) with or without muscle symptoms, but also 
potentially life-threatening rhabdomyolysis [22]. A much more 
important adverse effect, particularly when life-long treat-
ment is concerned, is diabetes mellitus [23]. Meta-analyses 
have associated statins with a 9–13% increase in incident 
type 2 diabetes, which translates to one new diagnosis of 
diabetes per 1,000 person-years of statin use [24–26]. This 
is of particular concern in individuals who are treated with 
high-intensity statin therapy since it has been shown that in 
this group for every 1,000 patient-years two additional cases 
of diabetes occur [27]. Recently it has been demonstrated that 
statin therapy increases the risk of incident type 2 diabetes 
even more than was supposed earlier. Based upon a recent 
Finnish study on 8,749 non-diabetic men aged 45–73 years 
in a six-year follow-up of the Metabolic Syndrome in Men 
(METSIM) trial, statin therapy appears to increase the risk for 
incident type 2 diabetes by up to 46%, even after adjustment 
for confounding factors, and the risk is dose-dependent for 
simvastatin and atorvastatin [28].
ONLY RCT OR ALL THE AVAILABLE EVIDENCE?
The US guidelines confine themselves to a single, hard source 
of evidence — RCTs — ignoring the much wider scientific 
basis of knowledge that is available. This is very different from 
the previous comprehensive US guidelines — the National 
Cholesterol Education Program Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in 
Adults (Adult Treatment Panel III) — NCEP ATP III guidelines 
[29]. Unlike this, the European guidelines are based on 
understanding that the knowledge concerning the causes of 
ASCVD and the trends in its occurrence, which are of the 
utmost importance for ASCVD prevention, has come from 
over a century of research from many diverse disciplines. So 
these guidelines considered not only RCTs but also other 
sources — clinical observations, basic science, pathological 
studies, genetic studies, Mendelian randomisation studies, 
epidemiology, meta-analyses, and systematic reviews. A good 
example supporting such a view is that the decline in ACVD in 
some countries such as Finland was associated with substantial 
changes in lifestyles, particularly nutritional habits, and with 
the consequent reduction in blood cholesterol that preceded 
the introduction of statins. Also, US guidelines are focused 
only on the drugs, more precisely only on statins, and doses 
that were tested in RCTs (although not always consequently), 
and from them only fixed-dose strategies were considered, 
which is quite different from real life situations. 
TREATMENT TO TARGETS  
OR NO LIPID TARGETS AT ALL?
One of the most controversial issues concerning the recent 
US guidelines is their statement that “treating to target is no 
longer recommended”. It is hard to understand why is it so 
because these guidelines, just like the European guidelines, as 
already stated, consider increased LDL-C as a causal factor for 
ASCVD [30]. Why do they not accept LDL-C also as a treat-
ment target? They have abandoned treating to LDL-C targets 
and instead encouraged physicians to prescribe low-, moder-
ate-, or high-intensity statin treatment depending upon the 
patient’s baseline risk, from which four statin benefit groups 
were identified. They made these recommendations about 
specific statin intensity, specifically high-intensity in order to 
achieve at least a 50% LDL-C reduction, moderate-intensity 




help to measure the performance and enable quality control 
in preventive cardiology and preventive medicine in general.
Although the US guidelines do not recommend titration of 
LDL-C to any pre-established target values, explaining this by 
the fact that none of the RCTs were so designed, they do recom-
mend deciding upon the use of statins in primary prevention 
using a mixed pool risk calculator, despite the fact that none of 
the RCTs were designed based upon this calculator data, and 
that this calculator has not been fully evaluated. This is another 
inconsistency of the US guidelines showing that the approach 
based solely on RCTs has not been consistently applied. The 
reason is most probably because such a rigid approach cannot 
be consistently applied at all in real world circumstances. Where 
consistency is concerned, it has to be mentioned also that, for 
example, although some important and widely prescribed doses 
have not been tested in RCTs, they are recommended in the 
US guidelines because they simply could not be ignored. The 
notion that physicians should consider decreasing the statin 
dose if LDL-C is less than 1.03 mmol/L on two occasions also 
does not have any RCT evidence base, despite the fact that 
RCTs were declared as the sole criterion for these guidelines. On 
the contrary, recent studies have shown that achieving much 
lower LDL-C levels is quite safe and could be recommended 
in some very high-risk patients.
WHAT TO DO WITH STATIN  
INTOLERANT PATIENTS?
As already mentioned, unlike the European guidelines, which 
recommend also the use of some non-statin lipid-lowering 
drugs, the US guidelines are very inflexible concerning this 
issue and they recommend only statins as lipid-lowering 
drugs. They ignore the fact that roughly 10% of individuals 
cannot tolerate statins long term and that statin intolerance, 
which is today a widely accepted phenomenon, is a reality, but 
this issue has not been addressed in recent US guidelines at 
all [34, 35]. In a recent study on 647 patients with CAD who 
were prescribed statins, about 20% failed to have a significant 
LDL-C-lowering response to treatment, and these patients ex-
perienced a significant progression of atherosclerotic plaques 
over a follow-up period ranging from 18 to 24 months, as 
measured by intravascular ultrasound. The authors of this 
study have suggested that physicians who adopt “the latest 
ACC/AHA guidelines for the management of cholesterol” may 
follow a strategy of “prescribe and forget” in which they fail to 
monitor the effect of the statin; however, “the ACC/AHA has 
said they still encourage monitoring to determine the extent of 
LDL lowering”. Therefore, they suggest that for these patients 
step number one would be to increase their statin dose, which 
also supports ongoing monitoring. They have also stressed that 
if physicians interpret “prescribe and forget” as a principle for 
all statin doses, the atherosclerotic changes in these patients 
may still progress and they might still be at high risk of ASCVD 
events [36]. Since the recent US guidelines have abandoned 
in order to achieve an LDL-C reduction less than 30%, de-
pending upon absolute risk within individuals. However, it 
has to be clearly stated that the percentage reduction and 
those numbers do not have any hard RCT evidence base, 
which was claimed as the sole criterion of the US guidelines 
since there was no RCT until today with 50% or 30% LDL-C 
reduction as a target. 
The recent European guidelines retained their commit-
ment to a targeted approach to LDL-C, as already accepted 
in previous European joint prevention guidelines [31] and 
defined LDL-C targets that were tailored to the level of risk, 
although RCTs have not, in general, examined all the dif-
ferent LDL-C targets systematically. Still, according to these 
guidelines, in patients at very high ASCVD risk the LDL-C goal 
is, as already mentioned, less than 1.8 mmol/L (~70 mg/dL) 
and/or a ≥ 50% LDL-C reduction when the target level cannot 
be reached, in patients at high risk the LDL-C goal is less than 
2.5 mmol/L (~100 mg/dL), and in subjects at moderate risk the 
LDL-C target is less than 3.0 mmol/L (~115 mg/dL). Such an 
approach allows greater flexibility. One might, however, ques-
tion it claiming that targets are not evidence based enough. 
Nevertheless, it has been clearly shown, for example, that 
extrapolating from the available data, an absolute reduction 
to an LDL-C level of less than 1.8 mmol/L (~70 mg/dL) or 
at least a 50% relative reduction in LDL-C provides the best 
benefit in terms of ASCVD reduction in subjects with very 
high risk, and therefore such a recommendation is given in 
the European guidelines [32]. This “at least 50%” is similar to 
the percentage from the US guidelines but is given only as an 
alternative if the 1.8 mmol/L target could not be achieved. 
Namely, it is clear that, for example, a decrease of only 
50% LDL-C of 8.0 or 10.0 mmol/L (~ 310 or 390 mg/dL) in 
a patient with FH would certainly not be enough to prevent 
efficiently ASCVD. 
The US approach contrasts the fact that many physicians, 
particularly during the last decade or more, have adopted the 
philosophy that “lower is better” but also that such an ap-
proach has been accepted by patients with established ASCVD, 
who have been taught for many years to strive to reach their 
LDL-C target. Also, it is well known that patients wish to know 
their target values since this improves their adherence not 
only to drug treatment but also to lifestyle changes. Targets 
are important in physicians’ everyday practice, particularly 
considering doctor-patient communication, but they are also 
important to help optimise the patients’ compliance and to 
motivate the patients. Since guidelines are not produced only 
for cardiologists or lipidologists but also for a much broader 
medical audience, primarily for general practitioners who are 
overwhelmed by a plethora of guidelines for different diseases, 
they need clear, simple messages and user-friendly recommen-
dations, and such practitioners definitely favour target values 
[33]. They demand to have targets also because they help 
them to perform better services for their patients. Targets also 
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the pattern might follow what happened with antihypertensive 
treatment, which was also previously based on monotherapy 
[43]. However, although combined lipid-lowering treatment 
has been a reality in everyday clinical practice around the world 
for many years, the US guidelines still recommend only statin 
monotherapy. This is even less justified today after the publica-
tion of the results of the IMProved Reduction of Outcomes: 
Vytorin Efficacy International Trial (IMPROVE-IT), the first 
trial that has been able to demonstrate clearly an incremental 
clinical benefit by adding a non-statin agent to statin treat-
ment. This trial showed on 18,144 patients that the addition 
of ezetimibe to 40 mg/day of simvastatin in high risk patients 
with acute coronary syndromes who have LDL-C ≤ 125 mg/dL 
(~3.2 mmol/L) caused not only significantly lower LDL-C levels 
but also lower primary composite endpoint (cardiovascular 
death, nonfatal myocardial infarction, nonfatal stroke, rehos-
pitalisation for unstable angina, and coronary revascularisa-
tion) than statin monotherapy [44]. Therefore, if the patient 
is not getting the desired reduction in LDL-C, an additional 
lipid-lowering drug can be prescribed, as recommended by 
the European guidelines, in order to achieve adequate LDL-C 
lowering. Indeed, recently a retrospective (from 1999 to 2013) 
observational study including 1,000 consecutive adults treated 
for hyperlipidaemia and followed up for ≥ 3 years compared 
the applicability of current European and US guidelines and 
concluded that the application of the US guidelines may be 
associated with undertreatment of high-risk patients due to 
suboptimal LDL-C response to high-intensity statins in clinical 
practice. This study also found that adding ezetimibe to a statin 
substantially increased the rate of the European guidelines 
LDL-C target achievement together with the rate of LDL-C 
lowering response suggested by the US guidelines [45].
WHAT ABOUT THE RESIDUAL RISK?
The so-called “residual risk” is attributed either to the 
fact that a significant number of individuals retain a high 
ASCVD risk despite achieving the recommended LDL-C target 
levels by high-intensity statin treatment, or to the fact that 
many subjects treated with statins still have low HDL-C and 
elevated triglycerides [46]. Such a lipid disturbance, often 
called atherogenic dyslipidaemia, is typically encountered in 
high-risk patients with metabolic disorders like type 2 diabetes 
and/or obesity, which have an increasing prevalence but are 
largely under-diagnosed and under-treated [8, 47]. Although 
the contribution of low HDL-C and elevated triglycerides in 
increasing the ASCVD risk is still, at least to a certain degree, 
controversial the problem of residual risk has not been ad-
dressed at all in the US guidelines, and they totally ignore the 
wealth of evidence on the role of triglyceride-rich lipoproteins, 
remnants, conditions associated with low HDL-C, and small, 
dense LDL particles. Nevertheless, all of these are discussed in 
the European guidelines, and appropriate recommendations 
for possible treatment options are given therein.
treating to LDL-C target values, not only the authors of this 
study but many other critics have objected that this might have 
the unintended effect of physicians prescribing statins with-
out adequately determining whether they are achieving the 
desired effect of adequately lowering LDL-C. Also, although 
the US guidelines emphasis of high-intensity statin therapy 
for very high-risk patients might be justified, the reality is that 
clinical practice comprises significant prescribing inertia, and 
many physicians simply do not use high doses of statins, even 
in patients who are likely to have the greatest benefit [36].
Indeed, since US guidelines do not advise the use of 
LDL-C monitoring for measuring the therapeutic efficacy 
of lipid-lowering treatment and patient compliance, such 
a “prescribe and forget” approach might have important 
implications for very high-risk patients because they might be 
left undertreated. Although for these individuals US guidelines 
recommend that after the maximum intensity of statin therapy 
has been achieved, the addition of a non-statin drug may be 
considered to further lower LDL-C to acceptable levels, these 
guidelines do not specify exactly what might be “acceptable 
levels” for these patients. Also, since these guidelines are exclu-
sively statin-oriented, they do not specify which non-statin drug 
might be used in combination treatment and in which doses.
“Prescribe and forget” of the “fire and forget” principle 
might also have another serious consequence — increased 
non-adherence. Already nearly a decade ago it was clearly 
demonstrated that adherence to statins is worse in patients 
treated on a “fire and forget” basis than in patients treated to 
a target cholesterol concentration, and that such a prescribing 
strategy is associated with worse cardiovascular outcomes [37]. 
The issue of adherence is, in everyday clinical work, by far 
the most important issue because 50% or more of all patients 
discontinue statins within one year of treatment initiation 
while after two years 75% of patients who were prescribed 
a statin for primary prevention and 40% of patients with an 
acute coronary syndrome were non adherent [38–40]. About 
9% of all ASCVD events in Europe could be attributed to poor 
adherence to cardiovascular medications alone [41]. The 
“prescribe and forget” approach will certainly increase these 
unfavourable statistics.
STATIN MONOTHERAPY OR A COMBINATION 
WITH OTHER LIPID-LOWERING DRUGS AS WELL?
An important difference between the European and US guide-
lines is that the European guidelines stress the importance of 
combined lipid-lowering treatment if the LDL-C targets are not 
met or, in patients with elevated triglycerides and low HDL-C, 
if lifestyle interventions and monotherapy with one lipid-low-
ering drug are not successful. Hence, despite the fact that at 
the time when these guidelines were issued, i.e. almost four 
years ago, most patients with dyslipidaemia were treated with 
statins as monotherapy, it is clear that this will change in the 




WHY MIGHT UNITED STATES GUIDELINES  
NOT BE APPLICABLE OUTSIDE THE  
UNITED STATES, INCLUDING EUROPE?
Although the European guidelines were developed for Euro-
pean countries and are based on data obtained from European 
populations, they have been adopted by quite a number of 
non-European countries as well. However, in the past many 
more countries outside the US, even some European countries, 
have followed US guidelines. This is the reason why it should 
be stressed that immediately after the publication of the recent 
US guidelines it has been hypothesised that the mixed pooled 
cohorts equation used in these guidelines is unsuitable for most 
parts of the world outside the US as these populations were 
not included [33]. This particularly concerns the Asia-Pacific 
region. The US guidelines recommendations on high-intensity 
statin treatment may not be feasible in some populations since, 
for example, in the Chinese population a higher incidence of 
myopathy has been noted already at much lower statin doses 
[48]. This might occur as well in Japan where, based upon 
a pharmacokinetic study, the maximum dose of rosuvastatin 
was set at 20 mg/day, which is half of the maximum 40 mg/day 
recommended in the US and Europe [49]. 
It has been presumed that the reduction in the primary 
prevention threshold from 20% to 7.5%, according to the 
recent US guidelines, would result in a significantly greater 
number of patients treated with statins and in many patients 
with higher doses of statins, so that in a significant number 
of regions of the world this would be unaffordable but would 
also lead to a greater number of adverse effects due to statin 
therapy. Indeed recently, based on a large study population 
of 8,742 subjects plus data obtained from the 2008–2010 
Korea National Health and Nutrition Examination Survey of 
16,892 adults, the Korean authors have concluded that adopt-
ing the new US guidelines would result in the treatment of 
almost all Korean men and women (≥ 60 years and ≥ 70 years 
of age, respectively) without evidence of ASCVD [50]. There-
fore, overestimating the risk and treating many more subjects 
with statins than is necessary would have serious financial as 
well as health consequences.
Although, based upon all the data discussed so far, the 
European guidelines seem to be a much more appropriate 
choice for European countries, the most important factor is 
their implementation. Concerning this, we have to realise 
that despite the fact that the majority of European physicians 
support the concept of preventive cardiology and treatment to 
the lipid target values, this still does not always reflect in their 
current practice, the knowledge of graduated medical students 
on dyslipidaemia and its treatment is not satisfactory and the 
general public perceptions, knowledge, and awareness of 
ASCVD risk factors including dyslipidaemia are insufficient 
[51–53]. Obviously, there are still challenges and many bar-
riers to implement the guidelines [54]. Some of the barriers 
to more effective management of dyslipidaemia, particularly 
concerning lipid-lowering drug therapy, are also the financial 
constraints, especially in low- and middle-income European 
countries, as demonstrated by the data on differences in 
achieving lipid goal values in different countries [55, 56].
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